Inmolecule Nanotech (XPAR:MLINA) Current Deferred Revenue: €0.00 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
7 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Current Deferred Revenue?

Inmolecule Nanotech XPAR:MLINA 7 Current Deferred Revenue is €0.00 Mil as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 7/100. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Inmolecule Nanotech's current deferred revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.

Inmolecule Nanotech Current Deferred Revenue Related Terms

Inmolecule Nanotech Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Current Deferred Revenue Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Current Deferred Revenue
0.00 0.00

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
Current Deferred Revenue 0.00 0.00
XPAR:MLINA
7GF Score
Inmolecule Nanotech SA XPAR:MLINA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
Inmolecule Nanotech (XPAR:MLINA) has a Current Deferred Revenue of €0.00 Mil as of Dec. 2024. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Inmolecule Nanotech and its competitors.
Is Inmolecule Nanotech's Current Deferred Revenue too high?
Inmolecule Nanotech's current Current Deferred Revenue is €0.00 Mil. Overall, Inmolecule Nanotech has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Current Deferred Revenue compare to VRTX and REGN?
Inmolecule Nanotech's Current Deferred Revenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Current Deferred Revenue of €0.00 Mil. The current Current Deferred Revenue is €0.00 Mil. Inmolecule Nanotech's overall GF Score™ is 7/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Current Deferred Revenue is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
7GF Score

Get the complete analysis for XPAR:MLINA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price